CO5550456A2 - Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf) - Google Patents
Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf)Info
- Publication number
- CO5550456A2 CO5550456A2 CO05024529A CO05024529A CO5550456A2 CO 5550456 A2 CO5550456 A2 CO 5550456A2 CO 05024529 A CO05024529 A CO 05024529A CO 05024529 A CO05024529 A CO 05024529A CO 5550456 A2 CO5550456 A2 CO 5550456A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- amino
- aryl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
1.- Un compuesto de fórmula (la): o una sal, profármaco, tautómero, hidrato y solvato farmacéuticamente aceptable del mismo, en el queR1 es un anillo saturado, insaturado o aromático mono-, bi-, o policíciclo C3-C20 que contiene opcionalmente al menos un heteroátomo seleccionado del grupo constituido por N, O y S, en el que R1 además puede estar opcionalmente sustituido independientemente al menos con un resto seleccionado independientemente del grupo constituido por: carbonilo, halo, haloalquilo C1-C6, perhaloalquilo C1-C6, perhaloalcoxi C1-C6, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, hidroxi, oxo, mercapto, alquitio C1-C6, alcoxi C1-C6, arilo C5-C10, o heteroarilo C5-C10, ariloxi C5-C10, o heteroariloxi C5-C10, (ar C5-C10)alquilo C1-C6 o (heteroar C5-C10)alquilo C1-C6, (ar C5-C10)alcoxi C1-C6 o (heteroar C5-C10)alcoxi C1-C6, HO-(C=O)-, éster, amido, éter, amino, aminoalquilo C1-C6, (alquil C1-C6)aminoalquilo C1-C6, di(alquil C1-C6)aminoalquilo C1-C6, (heterociclil C5-C10)alquil C1-C6, (alqui1 C1-C6) y di(alquil C1-C6)amino, ciano, nitro, carbamoilo, (alquil C1-C6)carbonilo, (alcoxi C1-C6)carbonilo, (alquil C1-C6)aminocarbonilo, di(alquil C1-C6)aminocarbonilo, (aril C5-C10)carbonilo, (aril C5-C10)oxicarbonilo, (alquil C1-C6)sulfonilo, y (aril C5-C10)sulfonilo;cada R3 se selecciona independientemente del grupo constituido por: hidrógeno, halo, haloalquilo C1-C6, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, perhaloalquilo C1-C6, fenilo, heteroarilo C5-C10, heterociclo C5-C10, cicloalquilo C3-C10, hidroxi, alcoxi C1-C6, perhaloalcoxi C1-C6, fenoxi, (heteroaril C5-C10)-O-, (heterociclo C5-C10)-O-, (cicloalquil C3-C10)-O-, (alquil C1-C6)-S-, (alquil C1-C6)-SO2-, (alquil C1-C6)-NH-SO2-, -O2N, -NC, amino, -Ph(CH2) 1-6HN, -(alquil C1-C6)-HN, (alquil C1-C6)amino, [(alquil C1-C6)]2-amino, (alquil C1-C6)-SO2-NH-, amino-(C=O), -amino-O2S-, (alquil C1-C6)-(C=O)-NH-, (alquil C1-C6)-(C=O)-[(alquil C1-C6)-N]-, fenil-(C=O)-NH-, fenil-(C=O)-[(alquil C1-C6)-N]-, (alquil C1-C6)-(C=O)-, fenil-(C=O)-, (heteroaril C5-C10)-(C=O)-, (heterociclo C5-C10)-(C=O)-, (cicloalquil C3-C10)-(C=O)-, HO-(C=O)-, (alquil C1-C6)-O-(C=O)-, H2N-(C=O)-, (alquil C1-C6)-NH-(C=O)-, [(alquil C1-C6)]2-N-(C=O)-, fenil-NH-(C=O)-, fenil-[(alquil C1-C6)-N]-(C=O)-, (heteroaril C5-C10)-NH-(C=O)-, (heterociclo C5-C10)-NH-(C=O)-, (cicloalquil C3-C10)-NH-(C=O)- y (alquil C1-C6)-(C=O)-O-; ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41214602P | 2002-09-18 | 2002-09-18 | |
US48454303P | 2003-07-02 | 2003-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5550456A2 true CO5550456A2 (es) | 2005-08-31 |
Family
ID=32033585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05024529A CO5550456A2 (es) | 2002-09-18 | 2005-03-16 | Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf) |
Country Status (27)
Country | Link |
---|---|
US (4) | US6958354B2 (es) |
EP (2) | EP2165708A3 (es) |
JP (1) | JP4519657B2 (es) |
KR (1) | KR20050044807A (es) |
CN (1) | CN1681501A (es) |
AP (1) | AP2005003263A0 (es) |
AR (1) | AR041272A1 (es) |
AT (1) | ATE450258T1 (es) |
AU (1) | AU2003259475A1 (es) |
BR (1) | BR0314302A (es) |
CA (1) | CA2496295C (es) |
CO (1) | CO5550456A2 (es) |
DE (1) | DE60330362D1 (es) |
EA (1) | EA200500377A1 (es) |
EC (1) | ECSP055679A (es) |
ES (1) | ES2335099T3 (es) |
HR (1) | HRP20050247A2 (es) |
IS (1) | IS7698A (es) |
MA (1) | MA27440A1 (es) |
MX (1) | MXPA05002376A (es) |
NO (1) | NO20050838L (es) |
OA (1) | OA12929A (es) |
PA (1) | PA8583201A1 (es) |
PE (1) | PE20040988A1 (es) |
PL (1) | PL375979A1 (es) |
UY (1) | UY27985A1 (es) |
WO (1) | WO2004026306A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4547271B2 (ja) | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物 |
BR0314302A (pt) * | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
CA2578628A1 (en) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylpyrazoles as tgf-beta inhibitors |
WO2006028029A1 (ja) * | 2004-09-07 | 2006-03-16 | Sankyo Company, Limited | 置換ビフェニル誘導体 |
AU2005295734A1 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Alk5 조절제를 사용한 안압의 조절 |
EA016370B1 (ru) | 2006-10-31 | 2012-04-30 | Пфайзер Продактс Инк. | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов |
KR20100038119A (ko) * | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 raf 억제제로서 이의 용도 |
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
WO2017215506A1 (zh) * | 2016-06-13 | 2017-12-21 | 南京明德新药研发股份有限公司 | 作为TGF-βR1抑制剂的苯并三氮唑衍生的α,β不饱和酰胺类化合物 |
CA3039220A1 (en) * | 2016-10-26 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition |
EP3539957A4 (en) * | 2016-11-14 | 2020-05-13 | Jiangsu Hengrui Medicine Co., Ltd. | 3,4-BIPYRIDYL-PYRAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR AND MEDICAL USE THEREOF |
CN111936490A (zh) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
WO2019114792A1 (zh) * | 2017-12-13 | 2019-06-20 | 劲方医药科技(上海)有限公司 | 一种TGF-βRI抑制剂的晶型、盐型及其制备方法 |
WO2019136320A1 (en) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
WO2020003219A1 (en) * | 2018-06-29 | 2020-01-02 | Oat & Iil India Laboratories Private Limited | Substituted pyrazole derivatives as insecticides and fungicides |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
AU2019396360A1 (en) | 2018-12-11 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors |
CN110467601B (zh) * | 2019-08-29 | 2021-07-02 | 杭州市西溪医院 | 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用 |
TW202132297A (zh) | 2019-11-22 | 2021-09-01 | 美商施萬生物製藥研發Ip有限責任公司 | 經取代吡啶及使用方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (es) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4925857A (en) * | 1989-03-22 | 1990-05-15 | Sterling Drug Inc. | Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf阻害剤としてのピラゾール |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
MXPA03008142A (es) | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de bencimidazol. |
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
JP2005539000A (ja) | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 |
JP4547271B2 (ja) | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物 |
MXPA05002982A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf). |
BR0314302A (pt) * | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
OA12925A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
-
2003
- 2003-09-08 BR BR0314302-3A patent/BR0314302A/pt not_active IP Right Cessation
- 2003-09-08 JP JP2004568904A patent/JP4519657B2/ja not_active Expired - Fee Related
- 2003-09-08 DE DE60330362T patent/DE60330362D1/de not_active Expired - Lifetime
- 2003-09-08 MX MXPA05002376A patent/MXPA05002376A/es active IP Right Grant
- 2003-09-08 AU AU2003259475A patent/AU2003259475A1/en not_active Abandoned
- 2003-09-08 KR KR1020057004598A patent/KR20050044807A/ko not_active Application Discontinuation
- 2003-09-08 OA OA1200500078A patent/OA12929A/en unknown
- 2003-09-08 AP AP2005003263A patent/AP2005003263A0/xx unknown
- 2003-09-08 EP EP09177298A patent/EP2165708A3/en not_active Withdrawn
- 2003-09-08 PL PL03375979A patent/PL375979A1/xx not_active Application Discontinuation
- 2003-09-08 WO PCT/IB2003/003933 patent/WO2004026306A2/en active Application Filing
- 2003-09-08 EP EP03797443A patent/EP1542684B1/en not_active Expired - Lifetime
- 2003-09-08 AT AT03797443T patent/ATE450258T1/de not_active IP Right Cessation
- 2003-09-08 EA EA200500377A patent/EA200500377A1/ru unknown
- 2003-09-08 ES ES03797443T patent/ES2335099T3/es not_active Expired - Lifetime
- 2003-09-08 CA CA2496295A patent/CA2496295C/en not_active Expired - Fee Related
- 2003-09-08 CN CNA038222655A patent/CN1681501A/zh active Pending
- 2003-09-15 PE PE2003000940A patent/PE20040988A1/es not_active Application Discontinuation
- 2003-09-16 UY UY27985A patent/UY27985A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103356A patent/AR041272A1/es unknown
- 2003-09-17 US US10/667,189 patent/US6958354B2/en not_active Expired - Fee Related
- 2003-09-17 PA PA20038583201A patent/PA8583201A1/es unknown
-
2005
- 2005-02-16 NO NO20050838A patent/NO20050838L/no unknown
- 2005-02-17 IS IS7698A patent/IS7698A/is unknown
- 2005-03-16 CO CO05024529A patent/CO5550456A2/es not_active Application Discontinuation
- 2005-03-16 EC EC2005005679A patent/ECSP055679A/es unknown
- 2005-03-16 HR HR20050247A patent/HRP20050247A2/hr not_active Application Discontinuation
- 2005-03-18 MA MA28154A patent/MA27440A1/fr unknown
- 2005-09-23 US US11/234,564 patent/US7151110B2/en not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/557,638 patent/US7638537B2/en not_active Expired - Fee Related
-
2009
- 2009-11-12 US US12/617,027 patent/US20100056571A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5550456A2 (es) | Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf) | |
CO5550453A2 (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
CO5540390A2 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
CO5550458A2 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
CO5550473A2 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformadors (tgf) | |
ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
ECSP034551A (es) | Secretagogos de hormona del crecimiento | |
AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
PE20011233A1 (es) | Compuestos alquil aminoazepan-3-ona como inhibidores de proteasas | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
CA2527033A1 (en) | 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators | |
CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
CN1387514A (zh) | 芳族砜异羟肟酸金属蛋白酶抑制剂 | |
CO6160266A2 (es) | Derivado de oxopirazina y herbicida | |
ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
PE20040699A1 (es) | Compuestos de piperidina fenil sustituidos como activadores de ppar | |
MXPA06011826A (es) | Derivados de bis-fenil sulfinilo triciclicos aromaticos. | |
PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
KR100648133B1 (ko) | 펩티드 데포르밀라제 저해제로서 신규의 히드록사믹 산유도체 및 그 제조방법 | |
PE20040750A1 (es) | Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 | |
TW200616997A (en) | The preparation method for 6-substituted-1-methyl-1h-benzoimidazol derivatives and their preparation imtermediates | |
ES2602962T3 (es) | Derivado de fenilazol sustituido | |
CA2537942A1 (en) | Compounds and methods for treating dyslipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |